Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: Final results of a multicentric study in the United States

Leukemia Research

Volumn 38, Issue 9, 2014, Pages 1036-1040

  Rashidi, Armin ^a   Riley, Meghan ^b   Goldin, Teresa A ^c   Sayedian, Farzaneh ^d   Bayerl, Michael G ^b   Aguilera, Nadine S ^c   Vos, Jeffrey A ^d   Goudar, Ranjit K ^a,e   Fisher, Stephen I ^f  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

^e Virginia Oncology Associates   (United States)

^f Pathology Sciences Medical Group   (United States)

Author keywords

ATRA; Death; Leukemia; Promyelocytic

Indexed keywords

CYTOTOXIC AGENT; RETINOIC ACID;

ADULT; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; EARLY MORTALITY; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; THERAPY DELAY; UNITED STATES;

ATRA; DEATH; LEUKEMIA; PROMYELOCYTIC;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PATIENT ADMISSION; PATIENT TRANSFER; SURVIVAL ANALYSIS; TIME-TO-TREATMENT; TRETINOIN; UNITED STATES;

EID: 84906936607     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.06.011     Document Type: Article

References (23)

1. Douer D. The epidemiology of acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003, 16:357-367.
2. Fenaux P., Chevret S., Guerci A., et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000, 14:1371-1377.
3. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028.
4. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100:4298-4302.
5. Kanamaru A., Takemoto Y., Tanimoto M., et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995, 85:1202-1206.
6. Tallman M.S., Altman J.K. How I treat acute promyelocytic leukemia. Blood 2009, 114:5126-5135.
7. Sanz M.A., Tallman M.S., Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005, 105:3019-3025.
8. Ohno R., Asou N., Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003, 17:1454-1463.
9. British Committee for Standards in Haematology, Milligan D.W., Grimwade D., Cullis J.O., et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006, 135:450-474.
10. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, v. 2 2012, http://www.nccn.org.
11. Sanz M.A., Grimwade D., Tallman M.S., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
12. Altman J.K., Rademaker A., Cull E., et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013, 37:1004-1009.
13. Rashidi A., Goudar R.K., Sayedian F., et al. All-trans retinoic acid and early mortality in acute promyelocytic leukemia. Leuk Res 2013, 37:1391-1392.
14. Taylor F.B., Toh C.H., Hoots W.K., Wada H., Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
15. Sanz M.A., Lo Coco F., Martín G., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96:1247-1253.
16. Grimwade D., Howe K., Langabeer S., et al. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996, 94:557-573.
17. McClellan J.S., Kohrt H.E., Coutre S., et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 2012, 97:133-136.
18. Park J.H., Qiao B., Panageas K.S., et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011, 118:1248-1254.
19. Lehmann S., Ravn A., Carlsson L., et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011, 25:1128-1134.
20. Cordonnier C., Vernant J.P., Brun B., et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985, 55:18-25.
21. Di Bona E., Avvisati G., Castaman G., et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000, 108:689-695.
22. Jácomo R.H., Melo R.A., Souto F.R., et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 2007, 92:1431-1432.
23. Rego E.M., Kim H.T., Ruiz-Argüelles G.J., et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood 2013, 121:1935-1943.